Search clinical trials for: TAK-442

Total 5011 results

Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448

Prostatic Neoplasms | Prostate Cancer

France
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Takeda

Completed

TAK-114 Single- and Multiple-Dose Phase 1 Study

Clinical Pharmacology

Japan
Takeda

Completed

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

Influenza Infection
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Takeda

Completed

A Study of TAK-227 in Healthy Adults

Healthy Volunteers

United States
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Calithera Biosciences, Inc

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Advanced Nonhematological Neoplasms

Korea, Republic of, Japan, Taiwan
Takeda

Withdrawn

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Colorectal Cancer | Esophageal Neoplasms | Metastatic Pancreatic Cancer | Carcinoma, Non-small-cell Lung

United States, Japan
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Renal Impairment | Healthy Volunteers

Czechia, Hungary
Takeda

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Healthy Volunteers | Hepatic Impairment

Czechia, Slovakia
Takeda

Completed

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

Healthy Participants

China
Takeda

Terminated

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Lymphoma | Advanced Solid Tumors

United States
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Takeda

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Phase 1, TAK-648, Single-Rising Dose Study

Healthy Volunteers
Takeda

Recruiting

A Study of TAK-279 in Adults With or Without Kidney Problems

Renal Impairment | Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-103 in Adult With Solid Tumors

Solid Tumors

Japan
Takeda

Completed

A Study of Different Forms of TAK-994 in Healthy Adults

Healthy Participants

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Takeda

Completed

Open-label Study of TAK-875

Diabetes Mellitus

Japan
Takeda

Completed

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Breast Neoplasm | Ovarian Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Renal Neoplasm

United States
Takeda

Completed

A Study of TAK-510 in Healthy Adults

Healthy Participants

United States
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Takeda

Terminated

A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Neoplasms | Lymphoma | Hematologic Neoplasms

United States
Takeda

Active, not recruiting

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Solid Tumors

Japan
Takeda

Completed

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Nonhematologic Neoplasms, Advanced

Japan
Takeda

Completed

Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Prostate Cancer

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematological Malignancies

United States
Takeda

Completed

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Erosive Esophagitis

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Metastatic Melanoma | Advanced Non-hematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Takeda

Completed

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States

Search clinical trials for: TAK-442

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations